Nina Lynn Alesce

Dr. Nina Lynn Alesce


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2026 in Toxins
Verified
Journal Article
Open access
PDF file
APAtul T Patel
Atul T Patel
BCBilal Chughtai
Bilal Chughtai
AUAhunna Ukah Ukah
Ahunna Ukah Ukah
NANina Lynn Alesce
Nina Lynn Alesce
KIKimberly Becker Ifantides
Kimberly Becker Ifantides
GFGrace Forde
Grace Forde
OnabotulinumtoxinA (onabotA) is a neurotoxin that is FDA approved to treat multiple indications. However, data regarding the burden of these indications and onabotA utilization among older adults are limited. This analysis examined the prevalence of onabotA-approved indications and the proportion of those patients treated with onabotA in adults ≥65 years of age in Medicare Fee-for-Service (FFS; 2023) and Medicare Advantage (MA; 2022). Proportions of patients diagnosed with and treated for ≥2 indications were also estimated. Among FFS enrollees, 6.1% of patients were diagnosed with ≥1 indication and 7.0% of diagnosed patients received onabotA. Urological indications (3.2%) and spasticity (2.5%) were most commonly diagnosed, and 80%), and concomitant treatment of these indications was among the lowest (~5%). Differences in diagnosis and onabotA treatment rates by age, sex, and Medicaid eligibility were observed. OnabotA treatment rates among MA enrollees were lower. Among older adults, the most commonly diagnosed onabotA-approved indications had the lowest onabotA treatment rates, suggesting a potential gap between disease burden and real-world treatment utilization.